We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Arthritis Drug Tocilizumab Found Effective in Treating Sickest COVID-19 Patients

By HospiMedica International staff writers
Posted on 20 Nov 2020
Print article
Image: Anti-inflammatory drug tocilizumab (Actemra) (Photo courtesy of Roche)
Image: Anti-inflammatory drug tocilizumab (Actemra) (Photo courtesy of Roche)
Critically ill COVID-19 patients treated with the arthritis drug tocilizumab are significantly more likely to have improved outcomes, according to a new study.

The early findings, which are yet to be published, come from the REMAP-CAP trial, led by the Imperial College London (London, UK) and the Intensive Care National Audit & Research Centre (ICNARC) in the UK and Utrecht University (Utrecht, the Netherlands). The trial evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).

The results show that treatment with tocilizumab, an immunosuppressive drug used to treat rheumatoid arthritis, reached a key efficacy endpoint among critically ill patients with severe COVID-19, compared to patients who did not receive any immune modulation treatment. Patients receiving tocilizumab were more likely to improve (measured by a combination of organ support, such as a breathing machine, in the ICU and surviving the hospital admission) compared to patients who received no immune modulator.

The relative contribution of survival and reduced length of time needing organ support in ICU has not yet been analyzed. The trial does not yet know the relative benefits of tocilizumab compared to the other immune modulators. Further data are expected in the coming weeks and months. Due to the clinical implications for patients, the researchers have released the findings before they have been peer-reviewed, but are working to analyze and publish the full results as soon as possible.

“These early findings show that treatment with this immune modulating drug is effective for critically ill COVID-19 patients in intensive care units,” said Professor Anthony Gordon, Chair in Anesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust. “When we have the results available from all participants, we hope our findings will offer clear guidance to clinicians for improving the outcomes of the sickest COVID-19 patients.”

Related Links:
Imperial College London
Utrecht University


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Vibrating Mesh Nebulizer
Aerogen Solo

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.